{"links":{"html":"https://www.erudio.com/reports/persee-nct04547504","json":"https://www.erudio.com/reports/persee-nct04547504.json","markdown":"https://www.erudio.com/reports/persee-nct04547504.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"persee-04547504"}},"request":"https://www.erudio.com/contact?report=persee-04547504"},"offer":{"cited_commentary_sources":73,"verified_hcp_statements":217,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified speaker identities: the verified IDs of the people in the report, led by the NPI or their institution's staff page, so a Medical Affairs team can check that each statement is attributed to the right person: also X, Bluesky, LinkedIn and other web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For checking attribution inside the organization; never for outreach to or targeting of clinicians. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":60,"optional":true,"price_per_verified_person_usd":15,"price_usd":900,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"persee-nct04547504"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=persee-04547504","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/persee-nct04547504","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-03T18:46:49.473002Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":10,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":9,"title":"Primary endpoint: Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR)"},{"claim_count":12,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":11,"title":"Secondary endpoints"},{"claim_count":13,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":14,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":11,"title":"The comparison"},{"claim_count":12,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":10,"title":"Safety and tolerability"},{"claim_count":10,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":32,"coverage":"discussed","id":"A1","source_count":18,"title":"Selection beyond PD-L1: fitness, age, burden, comutations and patient preference"},{"claim_count":12,"coverage":"discussed","id":"A2","source_count":6,"title":"Conflicting endpoint accounts and historical monotherapy benchmarks"},{"claim_count":19,"coverage":"discussed","id":"A3","source_count":2,"title":"Driver exclusion, specimen adequacy and assay blind spots"},{"claim_count":19,"coverage":"discussed","id":"A4","source_count":1,"title":"Testing access, RNA standards, costs and peer education"},{"claim_count":20,"coverage":"discussed","id":"A5","source_count":2,"title":"Response-adapted treatment and decisions while molecular results are pending"},{"claim_count":10,"coverage":"discussed","id":"A6","source_count":6,"title":"Alternative regimens and local versus systemic intensification"},{"claim_count":17,"coverage":"discussed","id":"A7","source_count":11,"title":"Earlier comparative evidence and the need for prospective strategy trials"},{"claim_count":11,"coverage":"discussed","id":"A8","source_count":6,"title":"Patient priorities, shared decisions and unanswered outcome questions"},{"claim_count":16,"coverage":"discussed","id":"A9","source_count":14,"title":"Academic research, practical relevance and treatment intensity over time"}],"counts":{"cited_clinicians":44,"cited_clinicians_by_role":{"physician":12,"physician, Medical oncology":28,"physician, Pathology":1,"physician, Radiation oncology":3},"cited_physicians":44,"cited_sources":76,"claims_by_expression_type":{"comparison":11,"experience":7,"interpretation":49,"opinion":85,"primary_context":3,"question":18,"restatement":22,"uncertainty":15,"unspecified":7},"claims_by_kind":{"protocol_statement":1,"publication_statement":2,"source_observation":214},"clinician_statements":155,"evidence_units":196,"findings":10,"organisational_accounts":8,"people_cited":64,"people_identity_verified":60,"people_total":64,"screened_sources":129,"verified_claims":217},"findings_index":[{"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":1,"views":8},"has_counterview":true,"limitations":2,"links":{"context":0,"support":11},"ma_question":true,"named_voices":9,"passages":9,"sources":9,"sources_by_kind":{"commentary":9}},"title":"Speakers distinguish better disease control from unproven survival benefit and substantially greater toxicity"},{"id":"F2","structure":{"claims":13,"claims_by_group":{"comparisons":3,"experience":0,"questions":3,"restated":3,"views":4},"has_counterview":true,"limitations":3,"links":{"context":1,"support":13},"ma_question":true,"named_voices":4,"passages":11,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Whether comparator choice, conflicting endpoint accounts and historical benchmarks change interpretation"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":7},"has_counterview":true,"limitations":2,"links":{"context":0,"support":8},"ma_question":true,"named_voices":7,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Speakers see PERSEE as changing practice but disagree about a chemoimmunotherapy default"},{"id":"F4","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":0,"questions":5,"restated":0,"views":10},"has_counterview":true,"limitations":3,"links":{"context":1,"support":15},"ma_question":true,"named_voices":13,"passages":13,"sources":8,"sources_by_kind":{"commentary":8}},"title":"Speakers question PD-L1-only selection and propose clinical or molecular exceptions"},{"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":7},"has_counterview":true,"limitations":2,"links":{"context":0,"support":8},"ma_question":true,"named_voices":5,"passages":8,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Speakers question whether a negative molecular result adequately excludes a driver"},{"id":"F6","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":0,"views":9},"has_counterview":true,"limitations":2,"links":{"context":0,"support":12},"ma_question":true,"named_voices":5,"passages":12,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Speakers disagree over RNA-testing standards, feasibility and educational priorities"},{"id":"F7","structure":{"claims":16,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":0,"views":12},"has_counterview":true,"limitations":2,"links":{"context":2,"support":16},"ma_question":true,"named_voices":10,"passages":16,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Speakers choose different first-line sequences for a high-PD-L1 never-smoker with CNS disease"},{"id":"F8","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":3},"has_counterview":true,"limitations":3,"links":{"context":1,"support":7},"ma_question":true,"named_voices":7,"passages":8,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Speakers raise alternative regimens while warning against indirect extrapolation"},{"id":"F9","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":10},"has_counterview":true,"limitations":3,"links":{"context":1,"support":12},"ma_question":true,"named_voices":8,"passages":10,"sources":8,"sources_by_kind":{"commentary":8}},"title":"Speakers say earlier comparisons did not settle the chemotherapy question"},{"id":"F10","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":0,"views":7},"has_counterview":true,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":7,"passages":8,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Speakers praise academic evidence and emphasize patient-centered trade-offs"}],"medical_affairs_question":"Which patients gain enough early disease control to justify chemotherapy's burden, which can reasonably choose monotherapy, and how should that trade-off be explained without overstating survival or subgroup certainty?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Disease control, survival and toxicity are being weighed separately"},{"id":"section-2","level":2,"title":"Endpoint accounts and historical-control criticism require separate treatment"},{"id":"section-3","level":2,"title":"Practice-change judgments do not amount to chemotherapy for everyone"},{"id":"section-4","level":2,"title":"Selection beyond PD-L1 remains proposed rather than settled"},{"id":"section-5","level":2,"title":"Molecular exclusion depends on specimen and assay quality"},{"id":"section-6","level":2,"title":"RNA-testing debate concerns standards and access as well as detection"},{"id":"section-7","level":2,"title":"Treatment sequencing includes reasons to defer or withhold immunotherapy"},{"id":"section-8","level":2,"title":"Alternatives remain attached to their own regimens and evidence"},{"id":"section-9","level":2,"title":"Earlier evidence explains both anticipation and persistent disagreement"},{"id":"section-10","level":2,"title":"Academic value and patient priorities remain central"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR)"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F7","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":6}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":6},{"id":"F10","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F4","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-03T18:46:49.473002Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-03T18:59:11Z","record_hash":"090c4108523bf575aab31a0c4eb128083c51eb53dda072a43f567588b3813b96","release_hash":"b29c5611e2c1d874d460f0ab8ec79964524232428196f3e80b56615bbf0d82b7","report_id":"erudio-nct04547504","run_id":"7d34351b-08b1-40f1-a169-c4bf11d711ae","schema_version":"5.0","slug":"persee-04547504","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PERSEE tested adding chemotherapy to first-line pembrolizumab in PD-L1-high non-small-cell lung cancer; discussion weighs better disease control against unproven survival benefit and substantially greater toxicity. The report cites 44 physicians, including 28 medical oncologists, and contributors described in the sources reviewed for this edition as a PERSEE principal investigator or results authors. Views differ on a chemoimmunotherapy default, with PD-L1-only selection also questioned. Who gains enough early disease control to justify chemotherapy’s burden, who can choose pembrolizumab alone, and how should survival and subgroup uncertainty be explained?","meta_description":"129 sources screened · 217 verified statements (155 from clinicians verified by NPI or staff page) from 76 sources · 10 findings. Updated Nov 3, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-64da3410a2bd1efe6d12"],"id":"F2","paraphrase":"A medical oncologist on X asked whether PERSEE’s follow-up maturity should be considered when selecting a historical pembrolizumab benchmark.","publication_caveats":{"reason":"The sources reviewed for this edition do not state publication caveats for this thread.","status":"unavailable"},"source_channel":"x_thread","source_date":"2026-10-25","title":"Whether comparator choice, conflicting endpoint accounts and historical benchmarks change interpretation"},{"cited_claim_ids":["claim-c79122248c3103548ff0"],"id":"F10","paraphrase":"In an X thread, a medical oncologist asked about quality-of-life outcomes, subsequent treatments and the scope of subgroup reporting.","publication_caveats":{"reason":"The sources reviewed for this edition do not state publication caveats for this thread.","status":"unavailable"},"source_channel":"x_thread","source_date":"2026-10-25","title":"Speakers praise academic evidence and emphasize patient-centered trade-offs"}]},"publication":{"approved_at":"2026-11-03T18:59:11Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":129},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","Not yet captured in this edition: a view on first-line treatment selection, the limited role of added immunotherapy, and concerns about patient selection in prior evidence.","2 more clinician views in the sources used in this report are not yet captured as evidence in this edition.","182 passages in 80 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","63 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 33 sources about other trials or topics are not included.","The sources reviewed are not a representative sample of all HCPs. Some discussions were not fully assessed, one identified discussion could not be read, and unnamed or differently transcribed references may be absent.","Several organizational summaries, repeated posts and secondary relays describe the same presentation or publication. Their number cannot be interpreted as the number of independent clinicians endorsing a view.","The AI-voiced episode does not establish a named clinician as its narrator. “Rafael” is known only by first name in the relevant passage.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Sources describe some contributors' involvement in PERSEE, but those descriptions are not independent confirmation of trial roles and do not increase the evidentiary weight of their opinions.","Accounts conflict over primary-endpoint achievement, premature stopping and one interview PFS median. These discrepancies remain visible rather than being silently reconciled.","OS superiority is not established in the reported comparison; insufficient power and subsequent treatment complicate interpretation but do not prove either benefit or absence of benefit.","Subgroup, comutation and biomarker interpretations are often exploratory or proposed. Age, histology, sex and molecular features discussed here should not be read as validated treatment-selection rules.","Earlier indirect comparisons, retrospective analyses, PAULIEN and alternative-regimen discussions retain their own study, setting and timing; they are not PERSEE outcomes.","Full protocol and regulatory-label text were not available. The report cannot resolve every statistical-plan question or establish label compatibility.","The available statements do not resolve the requested quality-of-life, detailed molecular, subsequent-treatment or economic questions."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":4,"other":0,"podcast":1,"publication":2,"registry":1,"regulatory":0,"x_thread":67,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":73,"context":1,"methods":2},"count":76,"evidence_window":{"end":"2026-11-01","start":"2021-01-31"},"retrieval_snapshot":"2026-11-03T17:40:46.642748Z","timeline":[{"count":2,"week":"2021-W04"},{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W22"},{"count":1,"week":"2022-W02"},{"count":3,"week":"2022-W22"},{"count":1,"week":"2023-W17"},{"count":1,"week":"2023-W43"},{"count":1,"week":"2024-W05"},{"count":2,"week":"2024-W16"},{"count":2,"week":"2025-W43"},{"count":46,"week":"2026-W43"},{"count":14,"week":"2026-W44"}],"undated_sources":3},"quote_policies":[{"id":"clinicaltrials:NCT04547504:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04547504:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:34156285","quote_policy":"short_quote_link_out"},{"id":"pubmed:42927854","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-axbq3ziqaqvmkd22kzwpiil4-3mypuiahkfn2z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-axbq3ziqaqvmkd22kzwpiil4-3mypulszkzd2k","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cg5bjyxf74w3vg7lo4zqwpzg-3mz3havd65o27","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3myf7gtidi52l","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7508798346866655232","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7517841034651803648","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7517855484306014208","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7518688754816163840","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520056515517587456","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520069737352003584","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ea5bc3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1352711509001064450:3bb25c1f-6e8c-495f-8a5f-07aa0a1d6ea1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1355837096808894464:8e7ca413-6db1-42e1-9a58-209e832998a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1355885727016513538:31779f27-e25d-4ae7-bc54-51d8189ad77f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1380201382507073541:74a3ade0-ab01-4f9f-b6c1-5bb85d2cb339","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1400865273821937665:23f0cf3f-fbea-4d81-90f4-07d8bb5ab91b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1481256763529830407:13f27103-502b-40f2-a497-0cc20012b1cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532787838835642372:6dc45cb1-1efd-4e62-b396-74f71bf26011","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532794303843540993:4af2c62a-aa80-4808-a7a2-37e500fd1f7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532795267887529985:04a35ec1-1103-4981-beff-03001f8ceebe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1651484995477725186:a3b23dfd-29e4-4ed5-9c62-7c412fcc0e6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1668970254964326403:1444de81-5aec-4312-804d-ec9db30afd3d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716425774218011110:02707021-ff9c-47b2-b4a2-5f9da187dd52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1753710286341640704:21761cda-3931-41f4-ad08-782ceec8cfd1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1765309105055420637:c57d51f4-edbe-4e20-85aa-c17b29185869","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781329916354535660:05656788-320f-4fcf-ae9f-09431fd5b03c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781331393496162332:a65fc178-e391-4241-a856-113c689d505a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1942916688279670953:820a4efc-ca1f-4c90-9edd-1eb7bbc102b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980198568519667802:300e7824-d949-448f-836a-f4ff92c3eb4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980817504412004785:57095f97-b528-4d48-943d-707a7e87db46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102539871277682768:2b6a64bf-bb76-4172-9d72-b21e7c06bab6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102759893757469152:fb6bfcbf-27e0-4f2d-be2c-883c0ade6230","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103037435638661629:5e435e24-7913-4c7e-9138-0d3c828f3b62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107390688413339706:b17c3c31-43b8-41ec-b2a8-c07f203d5227","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110839917370560679:ce939625-6ca0-45c3-99b4-8d1c02394a8d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112077890926035089:9f03436d-6319-4dee-ac39-5208822f5f99","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112439291502559300:32e3790d-9528-464c-9f65-01cd6d63268b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112782606253371445:fe8c1e7e-77ef-4a2a-be80-1aaf0da48ab3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112846605963407601:e98c7409-89d3-4dda-90bd-9e9348cefece","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112867869759537359:41c5ee38-f46c-4e70-8695-11399f7c20ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112876572801745293:e0ed5b9c-8ed7-4b53-941e-1fd6afd9e4f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112892094314316200:f5f431dc-9f28-4fa3-93be-de1f3fa6c045","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112902318580752451:c7cdee7a-df28-47d9-b7f1-3ba731a4a576","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112911160416633189:db4ea10c-75d2-4ee8-aca1-b807937f8d81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112947042960240711:1f1b404b-0fe9-4e0a-803d-c58aad91b0f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112949787993727144:78efc76e-d7df-4cfa-be19-714139fb4659","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112953498870673883:c9afa878-6d99-4430-88a0-281beb4b1ea3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113027606589149376:d657b87c-f81b-424e-bb13-c67f49c4210e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113183440942059765:89f3d56b-5641-4a24-8a81-1e8ac82ab217","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113504311129129281:00ebb7cb-5498-46ad-849e-841b1552ef4d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113560490601300329:b62ffe3a-2345-4ecf-b25d-85578f5930ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113561393152540999:e27bd256-e61e-4763-849e-50910935d1ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113819441083682817:105bc1af-f0af-4b67-8f46-290b87dc2f7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114027566524936510:5d0c4d03-4d4c-4bac-82b4-47277654c6ba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114284580715061444:b4932ec3-b22c-4d39-bfc0-bbea43ba191c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114288508319760384:e6a2c2ed-e4e3-442e-ac84-1baafd2123b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114289050253418739:9fa3faeb-3309-45cb-be40-5affcfe1badb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114289340218323040:0d39e86a-acf5-47c1-b7bb-13721a7f85ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114289666841043252:a2449796-8fed-4fae-b8d8-7c7ab2650ebf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114289783698768338:71e0a39b-49e5-46f4-b4d7-c90cd3b8d472","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114289819367178377:598c564f-5bbd-4bb7-9963-6f1e3cfc0f9b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114290014053945779:5c98dfe5-1cb8-479a-a4f5-d132744e6346","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114290424529776836:5a26467c-8b4d-48af-b6cb-6537441cca84","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114290769284440529:bb7e4ce8-110a-427b-8258-75614be04b20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114290883575349315:d95b8fab-7527-481d-8bde-6ef495e5da0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114291954443833392:95e3ce20-40c2-460c-99ae-2ea0b77ece7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114291994830737458:ec337eb5-d16b-42f1-93b1-f438a5304340","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114292810782499216:73a17b3c-14eb-47e1-ae7c-326dd982a7e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114293402577576055:2228c123-d8f4-4363-adf6-93a4a0adc242","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114293935170339168:64c0158b-ab6a-44b1-a574-9d9a5f2c00e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114294538927812741:348f442b-7e62-4ab0-b278-17d24c7977ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114294578027331608:2905b8bc-f0f4-41de-baae-728874d30ab2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114295354480857105:cad61803-07fe-4549-9baf-be6d1193a377","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114295406943420482:44056aae-f56f-4937-b0b0-22b651ebb38a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114295640608182683:8d46b779-0f2a-401c-8d80-99586951cff0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114295872313761882:b19d85c0-e782-4428-a6f4-94aedc783a09","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114296324032004101:2b18f844-679a-43b5-90d5-adbb8194c61c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114296718137409772:66bec5be-1d6d-4a3c-ba0a-09e7302d11f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114299734059876421:0f608f7f-71c0-447a-9971-0dc089b2fabb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114300770824986833:16bba289-6a6f-4e02-bc61-74a01d337b5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114303002953826499:96ff1441-cd0f-4278-907a-8cc460e601d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114304410511724760:276f53de-e409-48a1-ac90-636066bcef1d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114306038140706938:f4ea7400-74e2-405b-93d1-9e908302fa08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114334285666631805:dbd09ca4-636b-4666-8ef6-4ff15a17007a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114336854887518696:f009eb97-3f61-4cdb-98c2-b8c1192429d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114338475377914128:ec457a8f-28ef-474c-8497-65e4cad32083","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114339298392650007:a6ea0d5a-8a06-4127-948d-20cde0fff84e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114352089212027232:3fcd29b3-e566-4e0b-b479-c76aa21777f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114357435628700133:18bdd4ac-cd4d-45b5-9b72-378f7ce378a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114359867297186228:efdecde2-5a2c-462b-a971-104d99007a1d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114373919763579211:3ca702fc-742b-4572-86e8-dac87a0bf189","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114384836471173477:2817b501-c842-4455-af52-bfebb88c34f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114428032974766475:5303cb7a-7f1f-4465-9499-4cbac2e0bd24","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114428535431434250:1f9664a1-a62f-4bf1-a7a2-33b0bda43405","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114431375755341957:b6e6fa1f-85d6-41ca-9596-45d43066f3bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114436571764326662:51090725-5d52-451d-a04c-5eca1512b46d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114440139737026975:dd7ae683-5020-4b3c-b241-9f08b732a533","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114457286538043693:ffd94ace-eccc-4fec-85fa-6984743fd3b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114457503022952842:8b3f7749-78e2-48eb-979c-46f744a9ad01","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114462557649953062:9f6de5bf-6a68-4e5a-bc8c-70b24bbb3adb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114463542711816423:45ad84fb-77ab-42cc-a1d2-2746baeea866","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114517667889476014:bbf42e00-0353-450b-bb97-aa26866b24fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114538788907016378:a7a35e9d-2ae5-47a9-bd92-6a5aea8f1ac1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114671811342594166:bb1c9059-05b6-421a-b1d0-d2b693453f8c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114686687397994786:e6218d96-7c95-4fa0-bd10-2bc0c396b052","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114710456845635711:b422c641-898e-47d7-a6e7-157e30787704","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114721527832662337:6e289dd6-9e40-463b-b50e-83e46fa2a174","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114747009748136062:1b3778bd-8e51-46eb-9648-3b9af8ef00b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114751359148847488:8b477720-f599-45a9-bb9f-007858b25416","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114842778471420333:2158e4c6-38f9-4b41-b6f2-6424835c1619","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114869693320450172:c361948b-02ef-4fea-a4b0-cd7374049782","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115024614317236523:785a6a5f-0689-47eb-ae88-0947a0d78cfa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115115309531041990:81e86c62-6f04-481f-880f-090167512a42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115121854436327897:f8ce5caa-4c7f-49b3-8eb0-249029a92e51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115405801678323998:67ef217e-4f18-4083-9186-d22703b255c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115601108882080091:dd21c18d-041a-43ea-ad38-31ab847fc259","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115736322581385315:80ef9e72-23ab-492b-b81d-93137aa60328","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115740488250863697:d58bb93e-d465-4c05-8b75-57806af39da6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115847362539344304:dcd183aa-8aa8-4bca-a601-c1660ea50fd9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115857678723395858:27fbf2f5-4db8-4f95-bdfa-21314f401614","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115859675023315400:1d6c9f0a-87a3-4081-8c3b-879b3da0c461","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115931970664374370:83c859d4-d290-485a-9d69-d762df00a1df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116097830934712685:1cd1fbd3-66c9-4f16-ac20-876923af9a43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116150485849612660:443776ca-1d5b-48a6-a73a-d3e5528ba415","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116495141376606578:72cff74b-e745-4adc-980e-2e288a7c8af7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116832784773755089:452f53da-8aa8-4b4b-957b-d13f0e9db58f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116889901182435492:096b2190-235b-4734-a113-d26c6b06da38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116923404204847176:e6252a17-e1e7-4591-be20-769eef19175b","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Td_5GNOKCRI","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":6,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":117,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":129},"count":129,"evidence_window":{"end":"2026-11-01","start":"2021-01-22"},"retrieval_snapshot":"2026-11-03T17:40:46.642748Z","timeline":[{"count":1,"week":"2021-W03"},{"count":3,"week":"2021-W04"},{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W22"},{"count":1,"week":"2022-W02"},{"count":3,"week":"2022-W22"},{"count":1,"week":"2023-W17"},{"count":1,"week":"2023-W24"},{"count":1,"week":"2023-W43"},{"count":1,"week":"2024-W05"},{"count":1,"week":"2024-W10"},{"count":2,"week":"2024-W16"},{"count":1,"week":"2025-W28"},{"count":2,"week":"2025-W43"},{"count":4,"week":"2026-W39"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":74,"week":"2026-W43"},{"count":32,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"reason":"Unmapped registry intervention: pembrolizumab and chemotherapy drugs","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"PERSEE","aliases":["PERSEE","PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%"],"brief_title":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","collaborators":["Groupe Francais De Pneumo-Cancerologie"],"conditions":["Non-small-cell Lung Cancer"],"display_condition":"first-line advanced NSCLC with PD-L1 ≥50%","display_interventions":[["pembrolizumab","platinum-based chemotherapy"]],"enrollment":{"count":349,"type":"ACTUAL"},"interventions":[{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pembrolizumab and Chemotherapy drugs","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04547504","official_title":"Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2025-12-22","type":"ESTIMATED"},"primary_endpoints":[{"description":"Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, according to RECIST 1.1 assessed by blinded inependant centra review (BICR)","measure":"Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR)","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months"}],"registered_date":{"date":"2020-09-14","type":"ACTUAL"},"registry_last_updated":"2025-09-17","registry_url":"https://clinicaltrials.gov/study/NCT04547504","short_name":"PERSEE","short_name_basis":"registry_acronym","sponsor":"University Hospital, Brest","start_date":{"date":"2020-12-22","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"29BRC20.0159_GFPC01-2020","type":"sponsor_study_id"},{"domain":"Groupe Français de Pneumo-Cancérologie","id":"GFPC 01-2020","type":"other"}],"study_type":"INTERVENTIONAL"}}}